A total of 211 cases of monkeypox have been reported in France this year. The French Public Health Agency issued a communique on the 11th, saying that 211 cases of monkeypox have been reported in France this year, including 2 new cases in the past two weeks. The communique said that these monkeypox patients are all adults, including 203 males and 8 females. According to reports, after viral gene sequencing, 168 cases were infected with monkeypox virus II, of which 61 cases were further diagnosed as infected monkeypox virus IIb. (Xinhua News Agency)New Oriental acquired Taimei International Travel Service. Tianyancha App shows that recently, Taimei (Beijing) International Travel Service Co., Ltd. has undergone industrial and commercial changes, and Tianjin Vision Contemporary Technology Co., Ltd., the original wholly-owned shareholder, has withdrawn, and Beijing New Oriental Wokaide International Education Travel Co., Ltd. has been added as a shareholder and wholly owned. At the same time, the legal representative and several key personnel have changed. Taimei (Beijing) International Travel Service Co., Ltd. was established in May 2016. Its legal representative is Longhua with a registered capital of RMB 5 million. Its business scope covers domestic tourism business, inbound tourism business, outbound tourism business, exhibition activities, conference services, ticketing agents and air ticket sales agents.The Nikkei 225 index closed at 39,881.10 points in early trading, up 1.29%.
Treasury futures rose by 0.30%, the 30-year main contract rose by 0.30%, and the 30-year main contract rose by 0.30%, a record high. The 10-year main contract rose by 0.12%, the 5-year main contract rose by 0.05% and the 2-year main contract rose by 0.02%.Hang Seng Science and Technology Index rose to 1%, while Kewang shares rose, with Billie Billie (09626.HK) rising by over 4%, Baidu (09888.HK) rising by 2.8%, Aauto Quicker (01024.HK), Tencent Holdings (00700.HK) rising by 1.8% and Alibaba (09988.HK) rising by over 1%.The total investment scale of Haiyouwei's factory in the United States may reach 10 million US dollars. According to Haiyouwei Science and Technology, on December 11th, Haiyouwei announced that it planned to set up a subsidiary in the United States to implement the polymer special membrane project. This project is a deepening cooperation between Haiyouwei and its industry partners on the basis of strategic and technical cooperation in the United States. It is an important measure to achieve the localized production and market-oriented extension of the company's photovoltaic packaging film in the American market. It is estimated that the total investment will not exceed 10 million US dollars.
Beijing Haidian Joy City will open on December 21st. According to WeChat official account news of "Beijing Haidian" WeChat, Haidian Joy City, the fourth joy city in Beijing, will open on December 21st. At present, many brands have come to an end, and the merchants in the venue have entered the preparations for opening. It is understood that Haidian Joy City is expected to introduce more than 280 brands.Shanghai's state-owned assets reform index rose, with the daily limit of First Medicine, Yimin Group, Kaikai Industry and Shanghai Phoenix, and Shanghai 900 rose by more than 8%.The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.
Strategy guide
12-14
Strategy guide
12-14